Cargando…

Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro

NLC containing Gefitinib (NANOGEF) was prepared using stearic acid, sesame oil and surfactants (sodium lauryl sulfate and tween 80). NANOGEFs were evaluated for particle size, polydispersity index (PdI), zeta potential, entrapment efficiency (EE), stability, release studies and cytotoxicity studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Makeen, Hafiz A., Mohan, Syam, Al-Kasim, Mohamed Ahmed, Attafi, Ibraheem M., Ahmed, Rayan A., Syed, Nabeel Kashan, Sultan, Muhammad Hadi, Al-Bratty, Mohammed, Alhazmi, Hassan A., Safhi, Mohammed M., Ali, Raisuddin, Intakhab Alam, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241461/
https://www.ncbi.nlm.nih.gov/pubmed/32329374
http://dx.doi.org/10.1080/10717544.2020.1754526
_version_ 1783537072723722240
author Makeen, Hafiz A.
Mohan, Syam
Al-Kasim, Mohamed Ahmed
Attafi, Ibraheem M.
Ahmed, Rayan A.
Syed, Nabeel Kashan
Sultan, Muhammad Hadi
Al-Bratty, Mohammed
Alhazmi, Hassan A.
Safhi, Mohammed M.
Ali, Raisuddin
Intakhab Alam, M.
author_facet Makeen, Hafiz A.
Mohan, Syam
Al-Kasim, Mohamed Ahmed
Attafi, Ibraheem M.
Ahmed, Rayan A.
Syed, Nabeel Kashan
Sultan, Muhammad Hadi
Al-Bratty, Mohammed
Alhazmi, Hassan A.
Safhi, Mohammed M.
Ali, Raisuddin
Intakhab Alam, M.
author_sort Makeen, Hafiz A.
collection PubMed
description NLC containing Gefitinib (NANOGEF) was prepared using stearic acid, sesame oil and surfactants (sodium lauryl sulfate and tween 80). NANOGEFs were evaluated for particle size, polydispersity index (PdI), zeta potential, entrapment efficiency (EE), stability, release studies and cytotoxicity studies (MTT assay). The optimized NANOGEF exhibited particle size of 74.06 ± 9.73 d.nm, PdI of 0.339 ± 0.029 and EE of 99.76 ± 0.015%. The TEM study revealed spherical shape of NANOGEF formulations. The slow and sustained release behavior was exhibited by all NANOGEFs. The effects of surfactants were observed not only on particle size but also on zeta potential, entrapment efficiency, stability and release studies. The MTT assay revealed 4.5 times increase in cytotoxicity for optimized NANOGEF (IC(50) = 4.642 µM) when compared with Gefitinib alone (IC(50) = 20.88 µM in HCT-116 cells). Thus NANOGEF may be considered as a potential drug delivery system for the cure of colon cancer.
format Online
Article
Text
id pubmed-7241461
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-72414612020-06-01 Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro Makeen, Hafiz A. Mohan, Syam Al-Kasim, Mohamed Ahmed Attafi, Ibraheem M. Ahmed, Rayan A. Syed, Nabeel Kashan Sultan, Muhammad Hadi Al-Bratty, Mohammed Alhazmi, Hassan A. Safhi, Mohammed M. Ali, Raisuddin Intakhab Alam, M. Drug Deliv Research Article NLC containing Gefitinib (NANOGEF) was prepared using stearic acid, sesame oil and surfactants (sodium lauryl sulfate and tween 80). NANOGEFs were evaluated for particle size, polydispersity index (PdI), zeta potential, entrapment efficiency (EE), stability, release studies and cytotoxicity studies (MTT assay). The optimized NANOGEF exhibited particle size of 74.06 ± 9.73 d.nm, PdI of 0.339 ± 0.029 and EE of 99.76 ± 0.015%. The TEM study revealed spherical shape of NANOGEF formulations. The slow and sustained release behavior was exhibited by all NANOGEFs. The effects of surfactants were observed not only on particle size but also on zeta potential, entrapment efficiency, stability and release studies. The MTT assay revealed 4.5 times increase in cytotoxicity for optimized NANOGEF (IC(50) = 4.642 µM) when compared with Gefitinib alone (IC(50) = 20.88 µM in HCT-116 cells). Thus NANOGEF may be considered as a potential drug delivery system for the cure of colon cancer. Taylor & Francis 2020-04-24 /pmc/articles/PMC7241461/ /pubmed/32329374 http://dx.doi.org/10.1080/10717544.2020.1754526 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Makeen, Hafiz A.
Mohan, Syam
Al-Kasim, Mohamed Ahmed
Attafi, Ibraheem M.
Ahmed, Rayan A.
Syed, Nabeel Kashan
Sultan, Muhammad Hadi
Al-Bratty, Mohammed
Alhazmi, Hassan A.
Safhi, Mohammed M.
Ali, Raisuddin
Intakhab Alam, M.
Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro
title Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro
title_full Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro
title_fullStr Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro
title_full_unstemmed Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro
title_short Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro
title_sort gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241461/
https://www.ncbi.nlm.nih.gov/pubmed/32329374
http://dx.doi.org/10.1080/10717544.2020.1754526
work_keys_str_mv AT makeenhafiza gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro
AT mohansyam gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro
AT alkasimmohamedahmed gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro
AT attafiibraheemm gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro
AT ahmedrayana gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro
AT syednabeelkashan gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro
AT sultanmuhammadhadi gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro
AT albrattymohammed gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro
AT alhazmihassana gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro
AT safhimohammedm gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro
AT aliraisuddin gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro
AT intakhabalamm gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro